TY - JOUR
T1 - Infection free “resisters” among household contacts of adult pulmonary tuberculosis
AU - for the CTRIUMPH RePORT India Study Team
AU - Mave, Vidya
AU - Chandrasekaran, Padmapriyadarshini
AU - Chavan, Amol
AU - Shivakumar, Shri Vijay Bala Yogendra
AU - Danasekaran, Kavitha
AU - Paradkar, Mandar
AU - Thiruvengadam, Kannan
AU - Kinikar, Aarti
AU - Murali, Lakshmi
AU - Gaikwad, Sanjay
AU - Hanna, Luke Elizabeth
AU - Kulkarni, Vandana
AU - Pattabiraman, Sathyamoorthy
AU - Suryavanshi, Nishi
AU - Thomas, Beena
AU - Kohli, Rewa
AU - Sivaramakrishnan, Gomathi Narayan
AU - Pradhan, Neeta
AU - Bhanu, Brindha
AU - Kagal, Anju
AU - Golub, Jonathan
AU - Gandhi, Neel
AU - Gupte, Akshay
AU - Gupte, Nikhil
AU - Swaminathan, Soumya
AU - Gupta, Amita
N1 - Funding Information:
Data in this manuscript were collected as part of the Regional Prospective Observational Research for Tuberculosis (RePORT) India Consortium. This project has been funded in whole or in part with Federal funds from the Government of India’s (GOI) Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR), the USA National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), the Office of AIDS Research (OAR), and distributed in part by CRDF Global. This work was also supported by NIH NIAID grants [R01AI097494 to JG, R21AI127149 to VM], the NIH funded Johns Hopkins Baltimore-Washington-India Clinical Trials Unit for NIAID Networks [UM1AI069465 to VM, NG, AG]; the Ujala Foundation, Newton Square PA, the Wyncote Foundation and Gilead Foundation. The authors also acknowledge support from Persistent Systems In-Kind. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the DBT, the ICMR, the NIH, or CRDF Global. Any mention of trade names, commercial projects or organizations does not imply endorsement by any of the sponsoring organizations. The sponsors had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. The CTRIUMPH team listed in alphabetical order—Aarti Kinikar, Akshay Gupte, Alamelu Raja, Amita Gupta, Amita Nagraj, Anand Kumar B, Andrea DeLuca, Anita More, Anju Kagal, Archana Gaikwad, Ashwini Nangude, Balaji S, Beena Thomas, Bency Joseph, Bharath TK, Brindha B, Chandrasekaran P, David Dowdy, Deepak Pole, Devanathan A, Devi Sangamithrai M, Dileep Kadam, Divyashri Jain, Dolla CK, Gabriela Smit, Gangadarsharma R, Geetha Rama-chandran, Hanumant Chaugule, Hari Koli, Hemanth Kumar, Jeeva J, Jessica Elf, Jonathan Golub, Jyoti Chandane, Kanade Savita, Kannan M, Kannan Thiruvengadam, Karthikesh M, Karunakaran S, Kelly Dooley, Lakshmi Murali, Lavanya M, Luke Hanna, Madasamy S, Madeshwaran A, Mageshkumar M, Mangaiyarkarasi S, Mahesh Gujare, Manoharan S, Michel Premkumar M, Munivardhan P, Murugesan S, Gomathy NS, Nagaraj, Neeta Pradhan, Nikhil Gupte, Nishi Suryavanshi, Chandrasekaran Padmapriyadarsini, Ponnuraja C, Premkumar N, Rahul Lokhande, Rajkumar S, Ranganathan K, Rani S, Rani V, Renu Bharadwaj, Renu Made-war, Rengaraj R, Rewa Kohli, Robert Bollinger, Rosemarie Warlick, Rupak Shivakoti, Sahadev Javanjal, Sandhya Khadse, Sathyamurthi P, Shalini Pawar, Shashank Hande, Shital Muley, Shital Sali, Shri Vijay Bala Yogendra Shivakumar, Suba priya K, Shyam Biswal, Silambu Chelvi K, Smita Nimkar, Soumya Swaminathan, Sriram Selvaraj, Sundeep Salvi, Sushant Meshram, Sur-endhar S, Swapnil Raskar, Uma Devi, Vandana Kulkarni, Vidula Hulyalkar, Vidya Mave, Vinod Tayawade, Vrinda Bansode, Yogesh Daware. We would like to acknowledge Katherine McIntyre for reviewing and copy editing the manuscript.
Publisher Copyright:
© 2019 Mave et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Despite substantial exposure to infectious pulmonary tuberculosis (TB) cases, some household contacts (HHC) never acquire latent TB infection (LTBI). Characterizing these “resisters” can inform who to study immunologically for the development of TB vaccines. We enrolled HHCs of culture-confirmed adult pulmonary TB in India who underwent LTBI testing using tuberculin skin test (TST) and QuantiFERON TB Gold Test-in-tube (QFT-GIT) at baseline and, if negative by both (<5mm TST and <0.35IU/mL QFT-GIT), underwent followup testing at 4–6 and/or 12 months. We defined persons with persistently negative LTBI tests at both baseline and followup as pLTBI- and resisters as those who had a high exposure to TB using a published score and remained pLTBI-. We calculated the proportion of resisters overall and resisters with complete absence of response to LTBI tests (0mm TST and/or QFT-GIT <0.01 IU/ml). Using random effects Poisson regression, we assessed factors associated with pLTBI-. Of 799 HHCs in 355 households, 67 (8%) were pLTBI- at 12 months; 52 (6.5%) pLTBI- in 39 households were resisters. Complete absence of response to LTBI tests was found in 27 (53%) resisters. No epidemiological characteristics were associated with the pLTBI- phenotype. LTBI free resisters among HHC exist but are uncommon and are without distinguishing epidemiologic characteristics. Assessing the genetic and immunologic features of such resister individuals is likely to elucidate mechanisms of protective immunity to TB.
AB - Despite substantial exposure to infectious pulmonary tuberculosis (TB) cases, some household contacts (HHC) never acquire latent TB infection (LTBI). Characterizing these “resisters” can inform who to study immunologically for the development of TB vaccines. We enrolled HHCs of culture-confirmed adult pulmonary TB in India who underwent LTBI testing using tuberculin skin test (TST) and QuantiFERON TB Gold Test-in-tube (QFT-GIT) at baseline and, if negative by both (<5mm TST and <0.35IU/mL QFT-GIT), underwent followup testing at 4–6 and/or 12 months. We defined persons with persistently negative LTBI tests at both baseline and followup as pLTBI- and resisters as those who had a high exposure to TB using a published score and remained pLTBI-. We calculated the proportion of resisters overall and resisters with complete absence of response to LTBI tests (0mm TST and/or QFT-GIT <0.01 IU/ml). Using random effects Poisson regression, we assessed factors associated with pLTBI-. Of 799 HHCs in 355 households, 67 (8%) were pLTBI- at 12 months; 52 (6.5%) pLTBI- in 39 households were resisters. Complete absence of response to LTBI tests was found in 27 (53%) resisters. No epidemiological characteristics were associated with the pLTBI- phenotype. LTBI free resisters among HHC exist but are uncommon and are without distinguishing epidemiologic characteristics. Assessing the genetic and immunologic features of such resister individuals is likely to elucidate mechanisms of protective immunity to TB.
UR - http://www.scopus.com/inward/record.url?scp=85069661298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069661298&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0218034
DO - 10.1371/journal.pone.0218034
M3 - Article
C2 - 31318864
AN - SCOPUS:85069661298
SN - 1932-6203
VL - 14
JO - PLoS One
JF - PLoS One
IS - 7
M1 - e0218034
ER -